PDS Biotech CEO Frank Bedu-Addo will join fellow industry leaders at #BioFuture2025 for a panel discussion, “Immunity Unleashed: Next-Gen Therapies & Immune Engineering,” focused on next-generation immunotherapies and the future of healthcare. For details: bit.ly/3zekWIg

PDS Biotech today announced that after review of the final VERSATILE-002 data, the Company has requested a meeting with the Food and Drug Administration (FDA) to explore an expedited approval pathway for PDS0101 in HPV16-positive head & neck cancer. bit.ly/47LF7Sa $PDSB

HPV16-positive head and neck cancer is projected to be the most dominant type of head and neck cancer in the US by the mid 2030s. PDS Biotech is exploring an expedited approval pathway to make PDS0101 available to patients sooner. Read more: bit.ly/47LF7Sa $PDSB

The proposed amendment to ongoing VERSATILE-003 trial is set to include PFS endpoint, based upon final VERSATILE-002 trial data. If the PFS endpoint is met, it would allow for an accelerated approval submission to the FDA. For details: bit.ly/47LF7Sa $PDSB

Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, comments on the recent announcement of an FDA meeting request to explore an expedited approval pathway for PDS0101 in HPV16-positive head and neck cancer: bit.ly/47LF7Sa $PDSB

Dr. Kirk Shepard, MD, Chief Medical Officer at PDS Biotech, highlights the Company’s efforts to shorten the time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer: bit.ly/47LF7Sa $PDSB

The FDA meeting request is based on final VERSATILE-002 results and a proposed amendment to VERSATILE-003 to reduce number of patients, while maintaining statistical power, and add PFS as an earlier primary endpoint for potential accelerated submission. bit.ly/47LF7Sa

Frank Bedu-Addo, Ph.D., CEO of PDS Biotechnology, comments on new clinical and translational data to be presented at the 2025 SITC Annual Meeting on the Company's novel investigational cancer therapies, PDS0101 and PDS01ADC: bit.ly/3LfOAZl #SITC25

At the upcoming 2025 Society for Immunotherapy of Cancer Annual Meeting, @TheNCI will highlight ongoing clinical and translational research across PDS Biotech's immunotherapy platforms in three abstracts, including one selected for a rapid oral abstract session. bit.ly/3LfOAZl #SITC2025 $PDSB

PDS Biotech today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2025 and provide a clinical programs update on Thursday, November 13th at 8:00 AM ET. To register, visit: bit.ly/4hHFAYW $PDSB

PDS Biotech today announced positive clinical and translational data presented at the Society for Immunotherapy of Cancer Annual Meeting. The presentations highlight immune-driven mechanisms and biomarkers that explain strong clinical activity of PDS0101 and PDS01ADC. bit.ly/47yUWMe #SITC25

A translational study showcased at the 2025 Society for Immunotherapy of Cancer Annual Meeting shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy. See key findings here: bit.ly/47yUWMe #SITC25 $PDSB

Recently presented data at #SITC25 shows that PDS Biotech's novel investigational immunocytokine, PDS01ADC, reprograms natural killer (NK) cells to possess characteristics that make them more active in killing cancer cells. Read more: bit.ly/47yUWMe $PDSB

Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech, comments on the positive clinical and translational data presented at the 2025 Society for Immunotherapy of Cancer Annual Meeting: bit.ly/47yUWMe #SITC25 $PDSB

New data shows that PDS01ADC promotes stem cell-like killer T cells and memory T cells that self-replicate and are therefore capable of potent and long-lasting anti-tumor activity. Read more on the data presented at #SITC25: bit.ly/47yUWMe $PDSB

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering: bit.ly/49a5frd $PDSB

PDS Biotech will host a conference call to report financial results for the quarter ended September 30, 2025 and provide a clinical programs update tomorrow, November 13th, at 8:00 AM ET. Join the live webcast here: bit.ly/47Pb8aV $PDSB

PDS Biotech today provided a business and clinical update and reported financial results for the third quarter ended September 30, 2025. See it here: bit.ly/47RQx5Q $PDSB

Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, comments on the Company's plan to seek accelerated approval pathway in the VERSATILE-003 Phase 3 trial. For more info, visit: bit.ly/47RQx5Q $PDSB

During the third quarter PDS Biotech announced the completion of VERSATILE-002 Phase 2 trial with results leading the Company to seek an accelerated approval pathway in the ongoing VERSATILE-003 Phase 3 trial design. See the clinical & corporate update: bit.ly/47RQx5Q